<DOC>
	<DOCNO>NCT01298011</DOCNO>
	<brief_summary>The main purpose research study evaluate whether Abraxane gemcitabine effective treating patient operable pancreatic cancer .</brief_summary>
	<brief_title>Study Gemcitabine Abraxane Treat Potentially Operable Pancreatic Cancer</brief_title>
	<detailed_description>The best outcome patient diagnose pancreatic cancer surgery . However many patient recurrence cancer successful surgery . The investigator evaluate chemotherapy surgery , new approach . In study , Abraxane gemcitabine test treatment people operable pancreatic cancer see surgery successfully perform treatment reduce cancer cell tumor surgery . Abraxane approve US FDA treatment metastatic breast cancer failure combination chemotherapy metastatic disease relapse within 6 month adjuvant chemotherapy . Gemcitabine approve FDA first line treatment patient locally advanced metastatic cancer pancreas .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patient histologically cytologically confirm potentially resectable adenocarcinoma pancreas . Patients islet cell neoplasms exclude . Definition potentially operable disease 1 . Staging highquality , pancreatic protocol , helical abdominal compute tomography require ( Endoscopic ultrasound require ) . 2 . No extension superior mesenteric artery ( SMA ) hepatic artery . 3 . Clear fat plane SMA celiac axis . 4 . No extension celiac axis hepatic artery . 5 . Patent superior mesenteric vein portal vein . 6 . No evidence distant extrahepatic disease CT scan . 7 . Pretreatment histological cytological confirmation adenocarcinoma . 2 . Male nonpregnant nonlactating female , ≥ 18 year age . 3 . If female patient childbearing potential , must negative serum pregnancy test ( β hCG ) document within 72 hour first administration study drug . 4 . If sexually active , patient must agree use contraception consider adequate appropriate Investigator . 5 . Patient must receive prior chemotherapy radiation pancreatic cancer exposure gemcitabine and/or Abraxane 6 . Patient follow blood count baseline : 1 . ANC ≥ 1.5 x 109/L ( 1500 /mm³ ) ; 2 . Platelets ≥ 100 x 109/L ; ( 100,000/mm³ ) ; 3 . Hgb ≥ 10 g/dL . 7 . Patient follow blood chemistry level baseline : 1 . AST ( SGOT ) , ALT ( SGPT ) ≤ 2.5 x upper limit normal ( ULN ) ; 2 . Alkaline phosphatase ( AP ) ≤ 2.5 X ULN ; 3 . Total bilirubin ≤1.5 mg/dl ; 4 . Serum creatinine ≤1.5mg/dl calculate clearance ≥ 50 mL/min/1.73 m² patient serum creatinine level &gt; 1.5 mg/dl . 8 . Patient acceptable coagulation status indicate PT within normal limit ( ±15 % ) PTT within normal limit ( ± 15 % ) . 9 . Patient ECOG performance status PS 01 . 10 . Patient informed nature study , agree participate study , sign Informed Consent Form prior participation studyrelated activity . 1 . Patient borderline resectable disease 2 . Patient use therapeutic coumadin history pulmonary embolus DVT . 3 . Patient active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy . 4 . Patient known infection HIV , hepatitis B , hepatitis C. 5 . Patient undergone major surgery , diagnostic surgery ( i.e.surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Day 1 treatment study . 6 . Prior chemotherapy radiation pancreatic cancer . Prior exposure gemcitabine and/or Abraxane . 7 . Patient history allergy hypersensitivity study drug . 8 . Patient serious medical risk factor involve major organ system Investigator considers unsafe patient receive experimental research drug . 9 . Patient unwilling unable comply study procedure . 10 . Patient enrol therapeutic clinical protocol investigational trial . 11 . Patient metastatic disease radiological staging . 12 . Patients age ≥ 80 exclude . As two event fatal sepsis see group study , candidate age group thoroughly evaluate enrollment study , ensure fit receive chemotherapy . In addition meeting baseline patient selection criterion , clinical judgment susceptibility infection expect stability performance status receive repeat weekly chemotherapy cycle , pay special attention . Patients enrol study hesitation consideration . Baseline criterion patient enrol study must carefully evaluate criterion follow appropriately .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>operable</keyword>
	<keyword>pancreas</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Preoperative</keyword>
	<keyword>potentially</keyword>
	<keyword>Pancreatic Cancer</keyword>
</DOC>